Loading...
ALT Altimmune
No Data
News
Comment
Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know
Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00. Shares of Altimmune are trading down 0.57% over the last 24 hour
Altimmune Is Maintained at Overweight by Piper Sandler
Altimmune Is Maintained at Overweight by Piper Sandler
Altimmune Price Target Cut to $25.00/Share From $34.00 by Piper Sandler
Altimmune Price Target Cut to $25.00/Share From $34.00 by Piper Sandler
Piper Sandler Maintains Overweight on Altimmune, Lowers Price Target to $25
Piper Sandler analyst Yasmeen Rahimi maintains Altimmune (NASDAQ:ALT) with a Overweight and lowers the price target from $34 to $25.
Altimmune analyst ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/18/2022 372.59% Piper Sandler $34 → $25 Maintains Overweight 06/30/2021 296.98% B. Riley Securities $41
Altimmune (NASDAQ:ALT) Price Target Cut to $25.00 by Analysts at Piper Sandler
Altimmune (NASDAQ:ALT – Get Rating) had its price objective cut by Piper Sandler from $34.00 to $25.00 in a research note issued to investors on Tuesday morning, The Fly reports. Several other analys
Piper Sandler Adjusts Altimmune's Price Target to $25 From $34, Reiterates Overweight Rating
04:42 AM EDT, 05/18/2022 (MT Newswires) -- Altimmune (ALT) has an average rating of buy and price targets ranging from $12 to $30, according to analysts polled by Capital IQ. (MT Newswires covers equi
Altimmune price target lowered to $25 from $34 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi lowered the firm's price target on Altimmune to $25 from $34 and keeps an Overweight rating on the shares. The analyst continues to have strong conviction for the
PTGX, FTCI and ADGI are among after hour movers
Gainers: DLocal Limited (DLO) +20%.Agilysys (AGYS) +14%.Intercure (INCR) +8%.Protagonist Therapeutics (PTGX) +5%.Fossil Group (FOSL) +5%.Losers: FTC Solar (FTCI) -8%.Knightscope (KSCP) -6%.Altimmune
HC Wainwright Reaffirms “Buy” Rating for Altimmune (NASDAQ:ALT)
Altimmune (NASDAQ:ALT – Get Rating)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a report released on Tuesday, TipRanks reports. They presently have a $25.00 price